Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
LIVE QUOTE
Bargain Hunters Dream
View Post
ENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with...
Therapy’s a trip for these Wall Street executives.
Wealthy stock traders are flocking to a Manhattan-based ketamine therapy practice that doles out the hallucinogenic drug in a lavish setting to...
We watched an excellent presentation from management at the Dawson conference and starting our due diligence now. Primary item of our interest is a joint...
Psychedelic Drug Helped People with Alcohol use Disorder Reduce Drinking, Study Shows (Today)
Psilocybin, the ingredient in magic mushrooms, along with talk...
Thus, to us, the key potential positive events that could lead to a rerating in PHRM.CN shares include publication of the Phase 2 trial data evaluating ketamine in LID-PD in...
